Analytical Market Review by DSM Group. December 2013.

As compared to October, FPP market size, measured in procurements price, decreased by 8.6% in November, amounting to 39.9 billion rubles (incl. VAT). According to pharmaceutical sales in the third month of autumn 2013, the medicines commercial market stood equal to 362.7 million packs in volume terms, which is 2.8% less than the same period in 2012.The medicine unit average cost on the commercial market in Russia decreased by 0.6% and amounted to 110 rubles in November 2013, if compared to October.

Based on the Laspeyres index, October 2013 showed 1% increase in prices in rubles. In dollar terms, the price index increased by 2.5%. All in all, inflation in pharmaceutical medicines prices has amounted to +3.9% in ruble terms and 0.7% in U.S. dollars, since the beginning of 2013.

The structure of the commercial FPP market in November 2013 has not fundamentally changed by its price sectorscompared to the same period in 2012. The proportion of medicines at the cost of 50-150 rub/package continued to decline (from 23.1 % in November 2012 to 20.4 % in November 2013); specific gravity of medicines at the cost of 150 to 500 rub/package has increased 0.5% (from 45.7 % to 46.2 %); low-price medicines (less 50 rub/package) weakened their position due to the reduction of their share from 8.5% to 7.4%. Medicines at a price of 500 rub/package and more occupied 26.0% of the commercial market in the third month of autumn 2013, which is 3.2 % more than in November 2012.

On November 2013 results, 57% of sold medicines are of home manufacture (in physical units). However, due to their low price against imported medicines, they account for 24% only, in value terms. In November 2012, the share of Russian products in physical units amounted to 58%, while the share in value terms was equal to 24%.

As of November 2013, the commercial market segment is represented as 52% of prescription medicines, and 48% of non-prescription medicines.

The three top ranking companies by their value sales volume in November are SANOFI-AVENTIS, NOVARTIS, and PHARMSTANDARD.

According to value pharmaceutical sales results in November 2013, the top brand medicines are ESSENTIALE (1.14% of total pharmaceutical sales), ACTOVEGIN (0.85%), and CONCOR (0.81%).

The volume of Russian pharmaceutical market of biologically active additives in value terms in November 2013 decreased by 5.0% compared to October and amounted to 2.4 billion rubles. In volume terms, the volume of Russian pharmaceutical market of biologically active additives in the third month of autumn 2013 decreased by 1.6% compared with the same period in 2012 and amounted to 27 million packages. Weighted average price of a package of biologically active additives increased by 0.7% and amounted to 89.3 rubles in November 2013 as compared to October.

in detail:

Leaving your personal data, you voluntarily consent to the processing of your personal data. Personal data refers to any information relating to you, as the subject of personal data (name, date of birth, city of residence, address, contact phone number, email address, occupation, etc.). Your consent extends to the implementation by the DSM Group of any actions regarding your personal data, which may be needed to collect, organize, store, clarify (update, change), processing (for example, sending letters or making calls), etc. subject to applicable law. Consent to the processing of personal data is given without a time limit, but may be revoked By you (it is enough to report this to). By sending your personal data to DSM Group, you confirm that they are familiar with the rights and obligations in accordance with the Federal Law "On Personal Data".